Refine your search

Search Results within category "Pain Management"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
6 Study Matches

"Alexa, I’m in pain! "A Real-Time Mindfulness Intervention to Control Pain: Delivery Through a Conversational Agent

We are interested in learning about people’s experiences with using the Amazon Alexa for delivery of a real-time mindfulness intervention to help with chronic pain management. Participation will include a free day-long introductory mindfulness training followed by daily use of mindfulness practices using the Amazon Alexa to establish a habit of use. The participants will use our developed Amazon Alexa app ("skill") and provide assessments. We will ask participants to complete short daily surveys and a follow-up interview.
Sebrina Doyle at sld40@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Individuals who had some experience with chronic pain over the last 6 months
Living in homes with internet access
Willing to use a smart-home device (Amazon Alexa)
Have access to a smart phone
Read, write, and speak English
Exclusion Criteria:
Under 18 years old
Major mental health issue that is not currently under advisement of a doctor/therapist
Actively struggling with addiction to substances or newly in recovery
Participants who currently report using mindfulness practices more than 1x a month
Pain Management
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Endometriosis-Associated Pain

Endometriosis is a common chronic condition that can cause pain in the lower part of the stomach (pelvis) during the menstrual period and at other times and pain during sexual intercourse. The purpose of this study is to test how effective and safe the investigational study drug, relugolix (rel-U-GO-lix), given with or without low-dose estradiol and norethindrone is in treating endometriosis-associated pain. Estradiol is a form of estrogen and norethindrone is form of progesterone. Both estrogen and progesterone are hormones normally made by women’s bodies. These hormones help control the menstrual cycle and menstrual periods and also support bone health. The study wants to know if endometriosis pain affects how women function, how they feel and if the study drug is effective and safe at treating the pain from endometriosis.
Heidi Watts at hwatts@pennstatehealth.psu.edu or 717-531-6272
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03204318
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Premenopausal female aged 18 to 50 years old
Has a diagnosis of endometriosis verified by surgery in the last 10 years
Has regular menstrual cycles (21 to 35 days long)
Has moderate, severe, or very severe pain during menstrual cycles
Is not expected to undergo gynecological surgery (or other surgical procedures for treatment of endometriosis) during the study
Exclusion Criteria:
Has a history of chronic pelvic pain that is not caused by endometriosis
Has had 4 or more prior laparoscopic, surgical, or other invasive procedure for endometriosis
Has had gynecological surgery or other surgical procedures for treatment of endometriosis within the 3 months prior to the Screening visit
Has unexplained vaginal bleeding outside of the patient’s regular menstrual period or pregnancy
Has a gastrointestinal disorder affecting absorption or gastrointestinal motility, history of or currently has osteoporosis or a systemic autoimmune disease
Pain Management, Women's Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3 multicenter, randomized, double-blind, placebo-controlled, clinical study to assess the efficacy and safety of linzagolix in subjects with moderate to severe endometriosis-associated pain.

The purpose of this study is to look at the safety and efficacy of different doses of linzagolix alone and together with so-called ‘add-back therapy’ (hormones) compared to placebo (an inactive sugar pill) in women with moderate to severe pain associated with endometriosis. Endometriosis is when tissue that normally grows inside the uterus grows outside the uterus. It is one of the most common gynecological diseases. The condition is mainly found in women in their reproductive years and disappears spontaneously after menopause. Symptoms can include painful periods, chronic pelvic pain, pain with bowel movement, pain during intercourse and urination problems. Linzagolix is an experimental drug which is not approved for the treatment of moderate to severe pain associated with endometriosis. Linzagolix has been shown to significantly reduce pain associated with endometriosis in women with endometriosis at once daily doses between 50 and 200 mg with a good safety and tolerability profile. About 450 women will take part in this study at a number of different locations in the US and Canada. This study will have up to 16 study visits over a period of approximately 15 months.
Heidi Watts at hwatts@pennstatehealth.psu.edu or 717-531-6272
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03986944
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Women aged 18
•49 years old
Has had surgery to diagnose endometriosis up to 10 years before screening
Has moderate to severe endometriosis associated pain
Must agree to take only those pain medications permitted by the study during participation
Exclusion Criteria:
Pregnant, planning to become pregnant or breastfeeding. If recently pregnant, must be at least 6 months post-partum or 3 months post-abortion/miscarriage
Surgical history of hysterectomy, Essure device, endometrial ablation resulting in amenorrhea, both ovaries removed, bowel resection or gastric bypass
Has had surgery for endometriosis in the last 6 months or planning surgery for endometriosis during study participation
Chronic narcotic use, alcohol or illicit drug abuse or prescribed medical marijuana
Pain Management, Women's Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for A Comparative Effectiveness Randomized Controlled Trial of Mindfulness Meditation versus Cognitive Behavioral Therapy for Opioi-Treated Chronic Low Back Pain

This study will use mindfulness meditation (MM) or cognitive behavioral therapy (CBT) on patients with chronic low back pain to help improve their health outcomes and reduce opioid dependence. Subjects will be randomized to the MM or CBT group and asked to complete at home or group activities while also completing surveys.
Amanda Taylor Gehman at ataylor6@pennstatehealth.psu.edu or 717-531-1283
All
18 year(s) or older
This study is also accepting healthy volunteers
NCT03115359
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adult 21+
Diagnosis of chronic low back pain
Treatment with pain medication for three months or more
Capable of providing informed consent
Exclusion Criteria:
Prior Mindfulness Meditation or Cognitive Behavioral Therapy training
Pregnant women
Diagnosed with borderline personality, delusional or bipolar disorders
Pain Management
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A volunteer study to determine the anatomical distribution of injectate, the extent of sensory block, and the pharmacokinetics of ropivacaine following Erector Spinae Plane (ESP) blocks.

This study will recruit healthy volunteers to determine the effect of a peripheral nerve block. The participants will get an injection in their back muscle after an intravenous line is placed in their hand or arm. After the injection they will have two MRI done at 30 and 90 minute time intervals. A half tablespoon of blood also will be taken through the IV line already placed 6 times during the study period starting just before to Peripheral nerve block placement up to four hours post injections. They will be discharged from the study after half an hour of the last blood sample. During this whole process they will be monitored for their blood pressure, oxygen saturation and other effects related to the procedure.
All
18 year(s) or older
This study is also accepting healthy volunteers
NCT03476642
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Healthy adults ages 18 to 60
Weight between 55kgs (~120lbs) and 100kgs (~220lbs)
Height 160cms (~5ft 3in) to 190cms (~6ft 3in)
Exclusion Criteria:
Pregnant females, chronic medical condition requiring medication
History of previous major spinal, abdominal or thoracic surgery, 4. Congenital abnormalities of the spine, back, thorax or abdomen
History of major trauma to the thorax or abdomen; 6. Allergy to ropivacaine or other amide local anesthetics
The presence of any metallic implant in their body, 9. Allergy to Gadolinium radiological contrast agent
Any contraindication to magnetic resonance imaging as determined by completion of a standard questionnaire administered to all patients undergoing magnetic resonance imaging.
Prevention, Muscle & Bone, Pain Management
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A randomized double-blind placebo controlled trial to assess the effectiveness of low-dose naltrexone in combination with standard treatment in women with chronic pelvic pain secondary to endometriosis.

Pelvic pain associated with endometriosis is in part due to inflammation of a layer of tissue in the abdomen (stomach area). This leads to the great potential of relieving endometriosis related pelvic pain in a non-narcotic medication by decreasing the inflammation. The purpose of this study is to evaluate how a low dose of naltrexone compared to placebo (inactive substance) impacts your daily pain and the quality of your life with endometriosis. Naltrexone is approved by the U.S. Food and Drug Adminstration (FDA) for the treatment of opioid overdose and addiction. At much lower doses, naltrexone has been shown to be beneficial in pain relief of inflammatory disorders with promising results, but the use of the low dose in this study to treat endometriosis pain is investigational and has not been approved by the FDA.
Heidi Watts at hwatts@pennstatehealth.psu.edu or 717-531-6272
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03970330
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Surgical diagnosis of endometriosis
Pelvic Pain associated with endometriosis
age 18-45
Exclusion Criteria:
Daily opioid use
Pregnant
Breast Feeding
Allergy to oxycodone, motrin, naltrexone
Pain Management, Women's Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA